Sartorius Stedim Bio

DIM
Real-time Euronext Paris - 08/22 05:35:04 pm
137.9EUR
-2.96%

The underlying trend is to the upside

Envoyer par e-mail
Jordan Dufee
Analyst

Strategy published on : 08/12/2019 | 03:12

long trade
Live

Entry price : 136.7€
Target : 155€
Stop-loss : 126€
Potential : 13.39%

Shares in Sartorius Stedim Biotech show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the € 155.

Summary

● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

● The company has solid fundamentals for a short-term investment strategy.


Strengths

● The company returns high margins, thereby supporting business profitability.

● The company is in a robust financial situation considering its net cash and margin position.

● Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.

● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 111.1 EUR


Weaknesses

● The company's "enterprise value to sales" ratio is among the highest in the world.

● With an expected P/E ratio at 49.53 and 43.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.

● The company is not the most generous with respect to shareholders' compensation.

● Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.

Zonebourse.com 2019
Envoyer par e-mail